Novavax

YTD

ALL

Trade Novavax 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NVAX

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines.

CEO

John C.s Jacobs

CEOJohn C.s Jacobs

Employees

749

Employees749

Headquarters

Gaithersburg, Maryland

HeadquartersGaithersburg, Maryland

Founded

1987

Founded1987

Employees

749

Employees749

NVAX Key Statistics

Market cap

1.44B

Market cap1.44B

Price-Earnings ratio

-5.23

Price-Earnings ratio-5.23

Dividend yield

—

Dividend yield—

Average volume

3.48M

Average volume3.48M

High today

$8.21

High today$8.21

Low today

$7.92

Low today$7.92

Open price

$8.01

Open price$8.01

Volume

1.23M

Volume1.23M

52 Week high

$11.97

52 Week high$11.97

52 Week low

$6.20

52 Week low$6.20

Stock Snapshot

As of today, Novavax(NVAX) shares are valued at $8.12. The company's market cap stands at 1.44B, with a P/E ratio of -5.23.

During the trading session on 2026-08-13, Novavax(NVAX) shares reached a daily high of $8.21 and a low of $7.92. At a current price of $8.12, the stock is +2.5% higher than the low and still -1.1% under the high.

Trading activity shows a volume of 1.23M, compared to an average daily volume of 3.48M.

Over the past 52 weeks, Novavax(NVAX) stock has traded between a high of $11.97 and a low of $6.20.

NVAX News

Simply Wall St 18h

How Novavax’s Earnings Slide and New Share Shelf Will Impact Investors

In August 2026, Novavax, Inc. reported that its second-quarter revenue fell to US$56.7 million from US$239.24 million a year earlier, swinging from net income o...

Simply Wall St 4d

Novavax Could Be 42% Undervalued Following Losses And Shelf Registration

Advertisement What the latest Novavax earnings mean for shareholders Novavax (NVAX) just delivered a sharp turn in its financial story. Second quarter 2026 re...

Simply Wall St 6d

Novavax Stock Faces Revenue Slump As Losses Deepen

Novavax stock inched up about 3% to US$7.95 into the Q2 print, a modest move for a biotech that just posted another quarterly loss. The headline this quarter is...

Analyst ratings

50%

of 8 ratings

Buy

50%

Hold

12.5%

Sell

37.5%

More NVAX News

Nasdaq 6d

Novavax Q2 Earnings Call Highlights

Novavax (NASDAQ:NVAX) reported second-quarter 2026 revenue of $57 million and a net loss of $53 million, while highlighting progress in its Sanofi partnership,...

People also own

Based on the portfolios of people who own NVAX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.